These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11555117)

  • 21. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
    Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
    Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
    Buti M; Valdés A; Sánchez-Avila F; Esteban R; Lurie Y
    Hepatology; 2003 May; 37(5):1226-7. PubMed ID: 12717407
    [No Abstract]   [Full Text] [Related]  

  • 23. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.
    Kim TH; Kim KA; Lim YS; Gwak GY; Yoon JH; Kang GH; Lee HS
    Intervirology; 2005; 48(4):230-8. PubMed ID: 15920347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The pegasys using and HCV genotype were the independent predictors of the response to antiviral therapy in chronic hepatitis C].
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Zhao GZ; Zhang SL; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):485-8. PubMed ID: 15329210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C.
    Mihm U; Hofmann WP; Kronenberger B; Wagner Mv; Zeuzem S; Sarrazin C
    J Hepatol; 2005 Apr; 42(4):605-6. PubMed ID: 15763349
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
    Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
    J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
    Bain VG; Kaita KD; Marotta P; Yoshida EM; Swain MG; Bailey RJ; Patel K; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):701-6. PubMed ID: 18467185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
    Patel MR; Mullen MP; Dieterich DT
    AIDS Read; 2006 Mar; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    Brandão C; Barone A; Carrilho F; Silva A; Patelli M; Caramori C; Focaccia R; Pereira L; Pedroso M; Tatsch F; Pessoa M;
    J Viral Hepat; 2006 Aug; 13(8):552-9. PubMed ID: 16901286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Virological response of chronic hepatitis C management with peg-interferon alpha-2b and ribavirin].
    Ma XJ; Li ZR; Li DM; Fan YM; Liao GX; Li TS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):721-3. PubMed ID: 17121241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.